Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

9.820 -0.340 (-3.35%)
Official Closing Price Updated: 8:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Notice of Patent Grant for CYB003 Breakthrough MDD Therapy Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss
The TDR Three Key Takeaways: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at Bloom Burton & Co. Healthcare Conference
Via Investor Brand Network
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Cybin Inc.
Via Business Wire
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Via Benzinga
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while. 
Via InvestorPlace
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming Public Ventures Discovery Day
Via Investor Brand Network
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Initiates Phase 2 Study of CYB004 for Generalized Anxiety Disorder
Via Investor Brand Network
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO
Via AB Newswire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Meeting with FDA to Review End of Phase 2 Study, Proposed Phase 3 Program
Via Investor Brand Network
Exposures Product Safety
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
From Cybin Inc.
Via Business Wire
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Via Benzinga
Exposures Product Safety
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives Share CYB003 Program Update During Webcast
Via Investor Brand Network
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
From Cybin Inc.
Via Business Wire
3 High-Potential Penny Stocks to Turn $1000 into $1 million
U.S. equities are in the midst of a steady rally, but these high-potential penny stocks are likely to trounce the major indices. 
Via InvestorPlace
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming TD Cowen Health Care Conference
Via Investor Brand Network
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
From Cybin Inc.
Via Business Wire
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Q3 Results, Recent Business Highlights
Via Investor Brand Network
Exposures Product Safety
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures Two New JP Patents, Further Broadening IP Portfolio in Key Markets
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
From Cybin Inc.
Via Business Wire
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.